deltatrials
Completed PHASE1 NCT00703586

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

A Two-Arm, Single Site, Proof of Concept Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc, a CCR5 Antagonist (ADARC 2007-02)

Sponsor: Aaron Diamond AIDS Research Center

Conditions HIV Infections
Interventions Maraviroc
Updated 6 times since 2017 Last updated: Oct 22, 2012 Started: Sep 30, 2007 Primary completion: May 31, 2011 Completion: May 31, 2011

Listed as NCT00703586, this PHASE1 trial focuses on HIV Infections and remains completed. Sponsored by Aaron Diamond AIDS Research Center, it has been updated 6 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Aaron Diamond AIDS Research Center
  • Pfizer
  • Rockefeller University
Data source: Rockefeller University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States